ECA certainly was not designed pre-trial. The bias is when clinicians have seen trial data -- in this case even just the interim trial analysis. And the bias is also with differences in inclusion criteria and dosing schedule. Post hoc ECA violates FDA guidance.
Market Data 
Markets 
AI
